Replicor is a clinical-stage biopharmaceutical company developing NUCLEIC ACID POLYMERS (NAPs). These compounds are oligonucleotides whose antiviral activity is strictly dependent on the sequence independent activity of phosphonothioate oligonucleotides as biocompatible polymers that interact with exposed hydrophobic surfaces in proteins.